We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current LRMR market cap is 207.69M. The company's latest EPS is USD -0.5791 and P/E is -1.71.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -10.34M | -14.16M | -16.73M | -24.6M | -18.26M |
| Net Income | -9.06M | -12.99M | -14.65M | -21.63M | -15.5M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -45.65M | -42.8M | -50.47M | -36.53M | -41.76M |
| Net Income | -45.41M | -42.48M | -50.64M | -35.36M | -36.95M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 103.95M | 95.94M | 248.21M | 237.16M | 219.02M |
| Total Liabilities | 11.24M | 14.22M | 17.36M | 25.76M | 20.62M |
| Total Equity | 92.71M | 81.72M | 230.84M | 211.4M | 198.4M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 80.73M | 104.69M | 78.67M | 126.41M | 95.94M |
| Total Liabilities | 27.11M | 14.99M | 14.25M | 15.5M | 14.22M |
| Total Equity | 53.62M | 89.69M | 64.41M | 110.9M | 81.72M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -24.12M | -33.46M | -10.41M | -24.4M | -48.95M |
| Investing | 35.98M | 33.35M | -68.36M | -131.86M | -104.58M |
| Financing | 30k | 30k | 162.15M | 161.82M | 161.85M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -40.78M | -42.2M | -42.11M | -27.57M | -33.46M |
| Investing | 25.26M | 17.09M | 24.17M | -90.96M | 33.35M |
| Financing | -5.26M | 93.59M | 19.89M | 75.26M | 30k |
| Market Cap | 207.69M |
| Price to Earnings Ratio | -1.71 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.36 |
| Price to Book Ratio | 0.77 |
| Dividend Yield | - |
| Shares Outstanding | 63.81M |
| Average Volume (1 week) | 433.45k |
| Average Volume (1 Month) | 606.76k |
| 52 Week Change | -20.80% |
| 52 Week High | 13.68 |
| 52 Week Low | 3.01 |
| Spread (Intraday) | 0.01 (0.31%) |
| Company Name | Larimar Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://larimartx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
